abstract |
The present disclosure relates to methods of treating or preventing diseases having increased levels of insulin-like growth factor I (IGF-I). The method includes administering to a subject in need a somatostatin analog having agonist activity in combination with an oligonucleotide that targets a growth hormone receptor (GHR). |